Yazarlar : Jenny Powers

Yayın : DGNews

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/improvement-haemotological-parameters-after-deferasirox-treatment-myelodysplastic-syndromes-and-iron?tsid=5

Konu : Diğer

Literatür İçeriği :  EDINBURGH -- May 24, 2011 -- Treatment with deferasirox reduced iron overload

in patients with transfusion-dependent myelodysplastic syndrome (MDS) and also
improved haemotological parameters, according to results of a post hoc analysis
presented here at the 11th International Symposium on Myelodysplastic Syndromes
(MDS).

Patients also showed greater erythroid, platelet, and neutrophil responses
following treatment with deferasirox.

Lead investigator Norbert Gattermann, MD, Heinrich-Heine-Universität,
Düsseldorf, Germany, reported results here on May 21 from a post hoc analysis
of the Evaluation of Patients’ Iron Chelation With Exjade (EPIC) study that
evaluated the haematologic responses in a large cohort of patients with MDS and
iron overload.

The EPIC study enrolled patients with a life expectancy of more than 1 year.
Deferasirox, an iron chelator, was given at 20 mg/kg/day to patients receiving
red-blood-cell transfusions of 2 to 4 units per month (7 to 14 mL/kg/month).
Initial dose could be adjusted from 5 mg/kg up to 40 mg/kg for patients
receiving less or more frequent transfusions. Erythroid, platelet, and
neutrophil responses were assessed according to the International Working Group
2006 criteria.

Of the 341 study participants, 279, 121, and 56 iron-overloaded patients with
MDS met the inclusion criteria for erythroid, platelet, and neutrophil response
analyses, respectively. The mean deferasirox dose for the erythroid, platelet,
and neutrophil analysis groups were 19.2, 19.4, and 18.4 mg/kg/day,
respectively.

Erythroid response, defined as haemoglobin increase of 1.5 g/dL or greater or a
reduction in RBC transfusions, was observed in 63 patients (22.6%).

Platelet response, defined as an increase of 30 x 10⁹/L
or greater (or by achieving at least 20 x 10⁹/L
in patients with less than 20 x 10⁹/L), was observed in
17 patients (14.0%).

Neutrophil response, defined as an increase of 100% or more and an absolute
increase greater than 0.5 x 10⁹/L, was seen in 11
patients (19.6%).

Deferasirox exposure was significantly shorter in platelet nonresponders than
in responders, 182 vs 364 days, respectively (P =.002). A
nonsignificant reduction in serum ferritin was seen in all haematological
groups.

This post hoc analysis support previous reports demonstrating that deferasirox
ameliorates iron overload, and may also improve haematologic parameters in MDS
patients.

Funding from this study was provided by Novartis Pharma AG.

[Presentation title: Improvement in Haematologic Parameters in Patients
With MDS Treated With the Iron Chelator Deferasirox (Exjade): An EPIC Study
Post-hoc Analysis. Abstract 149]

Literatür Arşivi